New phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01
COPENHAGEN, Denmark, November 6, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, announces new biomarker data from its phase 2 trial with personalized cancer vaccine EVX-01 in patients with advanced melanoma (skin cancer).
Covered in this story
Call it yourself
No calls on $EVAX yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Evaxion A/S →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.